← board
BDRX
distress 5/10 · elevated risk$1.72+1%today-97% from 52w high
Revenue
pre-revenue
Liquidity
$9M
Runway
1.5 yrs
Shares 1y
0%
Price & events
-84.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.6%
1D
-19.2%
1W
-35.3%
1M
-49.7%
3M
-84.0%
6M
-96.1%
1Y
-99.8%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $388.41B
- Volume
- 37.68K
- 52 Week Range
- $1.71 – $54.50
- Total Shares
- 225.82B
- Float Shares
- 605.88K
- Short %
- 9.02%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 9.19%
- RVOL
- 0.14x
- Beta
- 1.21
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $10 (+486% upside) · 1 analysts
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.